Borderline personality disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Borderline personality disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness and safety of AP707 in patients with borderline personality disorder. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-ap707-in-patients-with-borderline-personality-disorder/ Thu, 30 Apr 2026 13:08:55 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-ap707-in-patients-with-borderline-personality-disorder/ This study focuses on Borderline Personality Disorder, a mental health condition that can affect how a person manages emotions and relates to others. The purpose of the study is to evaluate how well the investigational drug AP707, which contains the substance adezunap, works and how safe it is for people with this condition. This medication is administered as an oromucosal spray, which is a liquid medicine applied directly to the inside of the mouth.

During the trial, participants are assigned to receive either AP707 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being given until the end of the study. This is done to ensure that the results are not influenced by expectations. Over a set period, the effectiveness of the treatment will be compared against the placebo to see if there are improvements in symptoms associated with the disorder.

]]> Study on Oxytocin and Self-Compassion Training for Patients with Borderline Personality Disorder https://clinicaltrials.eu/trial/study-on-oxytocin-and-self-compassion-training-for-patients-with-borderline-personality-disorder/ Wed, 29 Apr 2026 15:01:28 +0000 https://clinicaltrials.eu/trial/study-on-oxytocin-and-self-compassion-training-for-patients-with-borderline-personality-disorder/ This clinical trial is focused on studying the effects of a treatment for individuals with Borderline Personality Disorder (BPD). The treatment being tested combines a nasal spray containing oxytocin with a program called Self-Compassion Training (SCT). Oxytocin is a hormone that can influence social behaviors and emotions, and it is administered through a nasal spray in this study. The purpose of the study is to evaluate how this combination might help in the therapeutic process for people with BPD.

Participants in the study will receive either the oxytocin nasal spray or a placebo, which is a substance with no active medication. The study will involve regular sessions of Self-Compassion Training, which is designed to help individuals develop a kinder and more understanding attitude towards themselves. The study will take place over a period of time, during which participants will be monitored to assess the effects of the treatment on their symptoms and overall well-being.

The trial aims to explore whether the combination of oxytocin and SCT can improve self-compassion and reduce symptoms associated with BPD. Participants will be evaluated using various measures, including their levels of self-compassion, self-criticism, and overall satisfaction with life. The study hopes to provide insights into new ways of supporting individuals with BPD in their therapeutic journey.

]]> Ketamine Infusion Study for Symptom Improvement in Patients with Severe Borderline Personality Disorder https://clinicaltrials.eu/trial/ketamine-infusion-study-for-symptom-improvement-in-patients-with-severe-borderline-personality-disorder/ Wed, 29 Apr 2026 14:22:55 +0000 https://clinicaltrials.eu/trial/ketamine-infusion-study-for-symptom-improvement-in-patients-with-severe-borderline-personality-disorder/ This clinical trial is focused on studying the effects of a medication called Ketamine on individuals with a mental health condition known as Borderline Personality Disorder (BPD). BPD is a condition characterized by intense emotions, unstable relationships, and impulsive behaviors. The study aims to explore whether Ketamine, administered through an intravenous infusion, can help improve the symptoms of severe BPD. Participants will receive two doses of Ketamine at specific intervals, alongside their usual care.

The purpose of this study is to observe changes in the intensity of BPD symptoms over a short period. Participants will be monitored for changes in their symptoms from the start of the study to the ninth day. The study will also look at other aspects, such as changes in suicidal thoughts and depressive symptoms, as well as any potential side effects of Ketamine. The study will collect information on any new hospitalizations or emergency visits related to psychiatric issues during the study period.

This trial is a pilot study, meaning it is an initial, smaller-scale study to gather preliminary data. The information collected will help researchers understand the potential benefits and risks of using Ketamine for treating severe BPD and guide future research in this area. Participants will be closely monitored throughout the study to ensure their safety and well-being.

]]>